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ABSTRACT 
  
Despite the widespread use of pertussis vaccines during the last decades, pertussis has 
remained an endemic disease with frequent epidemic outbreaks. Currently two types of 
vaccines are used: whole-cell vaccines (WCVs) and recently developed acellular vaccines 
(ACVs). The long-term aim of our studies is to assess the effect of different vaccination 
policies on the population structure of Bordetella pertussis and ultimately on the disease 
burden in Europe. In the present study, a total of 102 B. pertussis isolates from the period 
1998 to 2001 from five European countries (Finland, Sweden, Germany, The Netherlands, 
and France) were characterized. The isolates were analyzed by typing based on variable 
number of tandem repeats (VNTR); by sequencing of polymorphic genes encoding the 
surface proteins pertussis toxin S1 and S3 subunits (ptxA and ptxC), pertactin (prn), and 
tracheal colonization factor (tcfA); and by fimbrial serotyping. The results reveal a relationship 
between geographic location and VNTR types, the frequency of the ptxC alleles, and 
serotypes. We have not observed a relationship between the strain characteristics we studied 
and vaccination programs. Our results provide a baseline which can be used to reveal 
changes in the B. pertussis population in Europe in the coming years.  
INTRODUCTION 
  
The introduction of whole-cell vaccines (WCVs) against pertussis in the 1940s to 1960s has 
resulted in a dramatic decrease in morbidity and mortality due to pertussis. WCVs were 
developed in the 1940s, when it was unclear which specific Bordetella pertussis antigens 
contributed to immunity. Further, there are large differences in the ways WCVs are produced 
by different manufacturers with respect to strains used, culture conditions, and inactivation 
procedures. This has resulted in WCVs with a wide range of efficacies (1, 25, 38, 40). Very 
effective WCVs have been used in the United Kingdom and France, whereas less effective 
WCVs have been used in Canada and The Netherlands (38, 40). In Sweden, vaccination with 
a WCV was discontinued in 1979 because of its low efficacy. The use of WCVs is associated 
with side effects such as local reactions, fever, and systemic symptoms. The reactogenicity of 
WCVs has stimulated the development of less reactogenic and more defined acellular 
vaccines (ACVs). A number of different ACVs have been developed, all of which contain 
pertussis toxin (Ptx). In addition to Ptx, the ACVs may contain filamentous hemagglutinin 
(FHA), pertactin (Prn), and fimbriae (Fim). Although field trials have shown that ACVs are less 
reactogenic than WCVs (8, 11-14, 34, 35), only a single ACV, comprised of Ptx, Prn, Fim, and 
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FHA, was shown to be as efficacious as a good WCV (19, 26). Because of their lower 
reactogenicity, ACVs have replaced WCVs in most developed countries.  
In Europe there is a high degree of heterogeneity with respect to vaccination history, the type 
of pertussis vaccines used, and the vaccination schedule. In order to investigate the effect of 
these differences on the incidence of pertussis and on the population structure of B. pertussis, 
a surveillance program was initiated entitled "European Research Programme for Improved 
Pertussis Strain Characterization and Surveillance" (acronym, EUpertstrain). One aim of this 
program is to identify vaccines and vaccination schedules that most effectively reduce 
pertussis morbidity and mortality, especially in the unvaccinated young. A second aim is to 
assess the effect of different vaccines on the B. pertussis population. Finally, this program 
allows the evaluation of the switch from WCVs to ACVs. Participating countries include 
Finland, Sweden, Germany, The Netherlands, and France. The vaccination programs of these 
countries are compared in Table 1.  
TABLE 1. Pertussis vaccines, vaccination schedules, and incidences in the five 
countries studied  
 
Protein variant expressed in vaccine 
Country VaccineManufacturer 
Start of 
vaccination 
(yr) 
% 
Coverage
Vaccination 
schedule Incidence/100,000
a
Vaccine 
strain PtxAf Prn FHA Fim TcfA 
Finland WCVb KTLc 1952 96 3, 4, 5, 24 
mo 
6-18 1772 PtxA2Prn1NDh Fim2,3ND 
     
       18530 PtxA4Prn1ND Fim3 ND      
Swedend ACV Glaxo-
SmithKline 
1996 100% 3, 5, 12 mo 11-31 TohamaPtxA2Prn1ND NPg NP 
     
 ACV Aventis-
Pasteur MSD 
1997 100% 3, 5, 12 mo 11-31  ND NP ND NP NP 
     
Germany 
(FRG) 
WCV Behringwerke 1955-1998 variable 3, 4, 5, 12-
15 mo 
  ND ND ND ND ND 
     
Germany 
(GDR) 
WCV State Institute1964-1989 >95    ND ND ND ND ND 
     
Germany ACV Glaxo-
SmithKline 
1995 >95 3, 4, 5, 11-
14 mo, 9-17 
yr, health 
care 
personnel 
6-20 TohamaPtxA2Prn1ND NP NP 
     
  Aventis-
Pasteur MSD 
1995 >95 3, 4, 5, 11-
14 mo, 9-17 
yr, health 
care 
personnel 
6-20  ND NP ND NP NP 
     
  Chiron-
Behring 
1995 >95 3, 4, 5, 11-
14 mo, 9-17 
yr, health 
care 
professional
6-20  ND ND ND NP NP 
     
The 
Netherlands
WCV NVIe 1953 96 3, 4, 5, 11 
mo 
14-44 134 PtxA2Prn1FhaB1 Fim3 TcfA2
     
       509 PtxA4Prn7FhaB2 Fim2 
or 
Fim2,3
TcfA2
     
France WCV Aventis-
Pasteur MSD 
1959 >90 2, 3, 4, 16-
18 mo (until 
1998) 
 IM1414 PtxA4Prn1ND Fim 2 
+ 3 
ND 
     
       IM1416 PtxA2Prn1ND Fim2 ND      
 ACV Glaxo-
SmithKline 
1998  16-18 mo, 
11-13 yr 
 TohamaPtxA2Prn1ND NP NP 
     
  Aventis-
Pasteur MSD 
1998  16-18 mo, 
11-13 yr 
  ND NP ND NP NP 
     
 
 
a
 Care should be taken when comparing incidences between countries, because of the 
different surveillance and diagnostic methods used.  
b
 Vaccine contains equal amounts of the two strains.  
c
 National Public Health Institute, Helsinki, Finland.  
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d
 In the Northern part of Sweden mainly a three-component ACV is used; in the southern part, 
a two-component ACV is used.  
e
 Netherlands Vaccine Institute, Bilthoven, The Netherlands.  
f
 PtxA, pertussis toxin S1 subunit.  
g
 NP, not present.  
h
 ND, not determined. 
 
  
In the present study, we compared B. pertussis strains circulating in the five countries in the 
period 1998 to 2001. A collection of 102 B. pertussis isolates were analyzed by typing based 
on variable number of tandem repeats (VNTR); by sequencing of polymorphic genes encoding 
the surface proteins pertussis toxin S1 and S3 subunits (ptxA and ptxC), pertactin (prn), and 
tracheal colonization factor (tcfA); and by fimbrial serotyping. This study may serve as a 
baseline to assess the effects of different vaccination policies in Europe on the incidence of 
pertussis. Ultimately, this may lead to improved vaccines against pertussis.  
MATERIALS AND METHODS 
  
Bacterial strains. A total of 102 B. pertussis isolates, from the period 1998 to 2001, were 
characterized in this study. French strains were from 1 year; Swedish, German, and Dutch 
strains were from 2 years; and the Finnish strains were from 3 years. An attempt was made to 
obtain an equal number of strains from vaccinated and unvaccinated individuals in the age 
category 0 to 4 years. However, due to limitations of the strain collections, this was not always 
possible. For example, in France no cases were observed in vaccinated children in the age 
category 0 to 4 years. Apart from these conditions, strains were randomly chosen from the 
collections. Approximately 20 strains per country were analyzed: 20 from Finland, 25 from 
Sweden, 17 from Germany, 20 from The Netherlands, and 20 from France. Of these isolates, 
55 were derived from unvaccinated hosts (ages 0 to 134 months) and 39 were from 
vaccinated hosts (ages 4 to 318 months). The vaccination status of eight German hosts was 
unknown.  
Vaccination status. Vaccination statuses of hosts from Sweden, Germany, and France were 
based on documented patient data. Vaccination status in Finland and The Netherlands was 
deduced from the hosts' age, which is reasonable in view of the high vaccination coverages.  
VNTR analysis. For VNTR analysis, the number of repeats for each VNTR locus was 
determined. VNTR analysis was performed using the primers for the five loci VNTR-1 and 
VNTR-3 to VNTR-6 as described before (32). Each PCR was carried out in a final volume of 
20 µl containing 20 pmol of the appropriate primer pair, 10 µl HotStarTaq Mastermix 
(QIAGEN), 1 M betaine, 1 µM 6-carboxyfluorescein-labeled forward primer, 1 µM reverse 
primer, and 20 ng of template DNA. Following an initial denaturation at 95°C for 15 min, 28 
cycles of 95°C for 20 s, 67°C for 30 s, and 72°C for 1 min were performed. The PCR was 
completed by a final extension phase of 68°C for 30 min using a GeneAmp 9700PCR system 
(Perkin-Elmer Applied Biosystems). Two microliters of 100-fold-diluted PCR products was 
added to a loading buffer containing 10 µl of formamide (Perkin-Elmer Applied Biosystems) 
and 0.05 µl of MapMarker LOW 70-400Bp (Bioventures Inc.). Before being loaded, the 
samples were denatured at 95°C for 5 min and then kept on ice. Fluorescently labeled 
amplicons were subjected to electrophoresis using an ABI PRISM 3700 automatic sequencer. 
The sizes of the PCR fragments were estimated using the GeneScan software package 
(Perkin-Elmer Applied Biosystem), and the exact number of complete repeats present was 
calculated using a derived allele-naming table based on the number of complete repeats 
which could theoretically be present in a PCR product of a given size, allowing for extra 
flanking nucleotides and primer size (Bionumerics software package version 3.0; Applied 
Maths).  
Sequencing of genes for polymorphic surface proteins. The four B. pertussis loci 
sequenced were the genes for antigens incorporated in the ACVs that are known to be 
polymorphic: e.g., genes coding for surface proteins pertussis toxin S1 and S3 subunits (ptxA 
and ptxC) and pertactin (prn). We also included the gene for tracheal colonization factor (tcfA) 
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as it was shown to be one of the most polymorphic B. pertussis proteins investigated so far 
(20, 38). The DNA sequences of these loci are available from GenBank. We have changed 
the designation of the genes for the pertussis toxin subunits to conform to the published 
genome sequence of B. pertussis (29). The designations ptxS1 and ptxS3 have been changed 
to ptxA and ptxC, respectively. Numbering of alleles has not been changed (20).  
PCR amplification of chromosomal DNA was performed by adding 1 µl of DNA to 19 µl of 
buffer comprising 50% HotstarTaq Master mix (QIAGEN), 1 µM concentrations of each 
primer, and 5 or 10% dimethyl sulfoxide. Five percent dimethyl sulfoxide was added to the 
PCR mix for amplification of ptxA, ptxC, and tcfA. For prn, 10% dimethyl sulfoxide was used. 
Amplification of genes was performed on a GeneAmp PCR 9700 system by using a specific 
program for each gene (22, 39). The amplified fragments were purified using a PCR 
purification kit (QIAGEN). Purified fragments were sequenced using the primers that were 
used in the initial amplification. Sequencing reactions were prepared using the ABI PRISM Big 
Dye Terminator Cycle Sequencing Ready Reaction kit (PE Applied Biosystems) according to 
the manufacturer's recommendations for cycle sequencing on the GeneAmp PCR 9700 
system. The reactions were analyzed on an ABI PRISM 3700 Genetic Analyzer (PE Applied 
Biosystems). Sequences were assembled using the SeqMan program of DNASTAR software.  
Serotyping. Serotyping of fimbriae was performed by slide agglutination with specific sera. A 
bacterial colony and a drop of serum that contained antibodies against Fim2 or Fim3 were 
mixed on a glass slide. After rocking for 1 minute, agglutination was determined.  
Statistical analysis. The statistical significances of the frequencies of VNTR, genotypes or 
serotypes in the different countries, between vaccinated and nonvaccinated hosts or type of 
vaccine used (WCV or ACV), were calculated using the 2 test. In cases in which conditions 
for 2 calculations could not be met (e.g., when all expected values are greater than 1.0 and 
at least 20% of the expected values are greater than 5), the exact test was performed.  
Genotypic diversity (GD) based on DNA typing was calculated by the equation GD = (n/[n – 
1]) x (1 – xi 2), where xi is the frequency of the DNA type, and n is the number of strains (37). 
Statistical significance of the difference in genotypic diversity between countries was 
calculated using the theory of U statistics (33). Statistical significance of the difference in 
genotypic diversity between vaccinated and unvaccinated was calculated using the method of 
jackknife (7).  
RESULTS 
  
Two approaches were used to characterize isolates: sequencing of virulence genes for 
polymorphic surface proteins and VNTR typing. B. pertussis isolates (n = 102) were selected 
from the period 1998 to 2001 from five different European countries (Finland, Sweden, 
Germany, The Netherlands, and France). From each country, 17 to 25 clinical isolates were 
analyzed which were derived from unvaccinated hosts (n = 55; age, 0 to 134 months; average 
age, 24 months) or vaccinated hosts (n = 39; age, 4 to 318 months; average age, 48 months). 
The vaccination status of eight German hosts was unknown.  
VNTR analysis. A total of 16 different VNTR types were identified in the 102 isolates. The two 
most common VNTR types identified (VT27 and VT29) accounted for 54% (55 of 102) and 
22% (22 of 102) of all the isolates analyzed, respectively (Table 2). These two profiles were 
found in all five countries, ranging in frequency from 40% in Finland to 76% to 90% in the 
other countries. Most of the remaining VNTR types were country specific, and 8% of the 
isolates generated a unique VNTR profile. The frequencies of the VNTR types in the five 
countries were significantly different (P = 0.0066). Differences in frequencies of VNTR types 
between vaccinated and unvaccinated hosts were not significant (P = 0.60). Based on VNTR 
types, the lowest GD in the B. pertussis population was found in the French bacterial 
population (GD = 0.51), whereas the highest diversity was found in the Finnish bacterial 
population (GD = 0.80). The GDs in Finland and Germany were significantly different from 
those in Sweden, The Netherlands, and France (P < 0.05). Isolates from vaccinated hosts 
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showed a higher GD compared to those from unvaccinated hosts (respectively, 0.715 and 
0.586). The difference was not significant, however (P > 0.05).  
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TABLE 2. VNTR type frequencies and genotypic diversities of B. pertussis in five 
European countriesa  
 
% (no.) of VNTR type in: 
VNTR 
type Finland (n = 20; 
GD = 0.80) 
Sweden (n = 25; 
GD = 0.56) 
Germany (n = 17; 
GD = 0.62) 
The Netherlands (n = 
20; GD = 0.52) 
France (n = 20; 
GD = 0.51) 
Grand total (% 
[n = 102]) 
16     5 (1) 1     
19 5 (1)     1     
22    5 (1)  1     
25   12 (2)   2     
27 30 (6) 60 (15) 53 (9) 60 (12) 65 (13) 54     
28 25 (5)     5     
29 10 (2) 24 (6) 24 (4) 30 (6) 20 (4) 22     
30  4 (1)    1     
43   6 (1)   1     
55 10 (2)     2     
71 5 (1) 8 (2)  5 (1)  4     
72 10 (2)     2     
73 5 (1)     1     
74     5 (1) 1     
75     5 (1) 1     
76  4 (1) 6 (1)   2     
 
a
 The number of strains analyzed is in parentheses. The distribution of the VNTR types was 
analyzed with the exact test. The frequencies of the VNTR types were significantly different 
between the five countries (P = 0.0066). n, number of strains in each country investigated. 
GDs in Finland and Germany were significantly different from GDs in Sweden, The 
Netherlands, and France (P < 0.05). 
Sequencing of genes for polymorphic surface proteins. Previous work revealed 
polymorphism in genes for the S1 and S3 subunits of pertussis toxin (ptxA and ptxC, 
respectively), pertactin (prn), and tracheal colonization factor (tcfA) (5, 38). The frequencies of 
the alleles for these genes in the five countries were compared.  
ptxC alleles. Two ptxC alleles, ptxC1 and ptxC2 (previously designated ptxS3-1 and ptxS3-2, 
respectively), have been described which differ at a single nucleotide resulting in a silent 
mutation (38). The ptxC1 allele was found to predominate in Finland and Sweden 
(respectively, 80% and 68% of the isolates), whereas ptxC2 predominated in Germany, The 
Netherlands, and France (76%, 70%, and 75% respectively) (Table 3). The frequencies of the 
two alleles in the five countries were significantly different (P = 0.0001). The frequencies of the 
two alleles in vaccinated and unvaccinated individuals were not significantly different (P = 
0.53; not shown).  
TABLE 3. Distribution of alleles in B. pertussis strains from different countries  
% (no. of strains) inb: 
Allelea 
Finland (n = 20) Sweden (n = 25) Germany (n = 17) The Netherlands (n = 20) France (n = 20) Total (n = 102) 
ptxC1 80 (16) 68 (17) 24 (4) 30 (6) 25 (5) 47 
ptxC2 20 (4) 32 (8) 76 (13) 70 (14) 75 (15) 53 
ptxA1 100 (20) 100 (25) 100 (17) 100 (20) 100 (20) 100 
prn1 5 (1) 0 (0) 6 (1) 0 (0) 5 (1) 3 
prn2 95 (19) 88 (22) 76 (13) 95 (20) 75 (15) 87 
prn3 0 (0) 12 (3) 18 (3) 5 (1) 20 (4) 10 
tcfA2 100 (20) 88 (22) 82 (14) 95 (19) 80 (16) 89 
tcfA3 0 (0) 12 (3) 18 (3) 5 (1) 20 (4) 11 
St-2 90 (18) 64 (16) 6 (1) 15 (3) 0 (0) 37 
St-3 10 (2) 20 (5) 94 (16) 85 (17) 90 (18) 57 
St-2 + 3 0 (0) 16 (4) 0 (0) 0 (0) 10 (2) 6 
 
a
 ptxC, pertussis toxin S3 subunit; ptxA, pertussis toxin S1 subunit; St, serotype.  
b
 The distributions of the alleles and serotypes were analyzed with the exact test. The 
frequencies of ptxC and the serotypes were significantly different in the five countries (P 
0.0001). The frequencies of the other alleles did not differ significantly between the countries. 
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ptxA alleles. Six ptxA alleles, which contain nonsilent mutations, have been found in B. 
pertussis populations (5, 18, 21, 22). All pertussis vaccines analyzed to date are derived from 
strains carrying the ptxA2 and ptxA4 alleles (previously designated ptxS1-2 and ptxS1-4, 
respectively), coding for the subunit variants PtxA2 and PtxA4, respectively (Table 1). A single 
ptxA allele, ptxA1 (previously designated ptxS1-1), was observed in this study (Table 3).  
prn alleles. Twelve prn alleles have been observed in B. pertussis populations, of which 3 
(prn1, prn2, and prn3) were found in this study (5, 18, 21, 22). The three alleles differ in 
nonsilent mutations. Vaccines used in Finland, Sweden, Germany, The Netherlands, and 
France are derived from strains producing the Prn1 variant (Table 1). This variant was found 
in low frequencies in all five countries (0% to 6%) (Table 3). Interestingly, all Prn1 strains (n = 
3) were isolated from nonvaccinated hosts. Strains with the prn2 allele predominated in all 
countries, ranging in frequency from 75% in France to 95% in The Netherlands. The frequency 
of prn3 strains ranged from 0 to 20%. No prn3 strains were observed in Finland. The 
frequencies of the three prn alleles in the five countries and in vaccinated and unvaccinated 
individuals (not shown) were not significantly different (P = 0.22 and 0.66, respectively, exact 
test).  
tcfA alleles. Five tcfA alleles have been described (38), of which two (tcfA2 and tcfA3) were 
found in this study. The two alleles differ in nonsilent mutations.The tcfA2 allele is found in the 
vaccines used to produce the French and Dutch WCVs. It is not known which tcfA alleles are 
present in the Finnish vaccine strains. TcfA is not a component of ACVs used in Sweden and 
Germany (Table 1). The tcfA2 allele predominated in all countries, ranging from 80% in 
France to 100% in Finland (Table 2). The frequencies of the two tcfA alleles in the five 
countries and in vaccinated and unvaccinated individuals (not shown) were not significantly 
different (P = 0.22 and 1.0, respectively).  
Fimbrial serotypes. B. pertussis produces two serologically distinct fimbriae, designated 
serotype 2 and serotype 3 fimbriae, respectively (17, 23). As strains may express a single 
serotype or both serotypes, three combinations are possible: serotype 2, serotype 3, and 
serotype 2 plus 3. WCVs used in the five countries harbor both fimbrial serotypes (Table 1). 
Fimbrial antigens are absent from ACVs used in Sweden, Germany, and France. Serotype 2 
strains predominated in Finland and Sweden (frequencies of 90% and 56%, respectively), 
whereas serotype 3 strains predominated in Germany, The Netherlands, and France 
(frequencies of 94%, 85%, and 90%, respectively) (Table 3). Serotype 2-plus-3 strains were 
only found in Sweden and France (frequencies of 8% and 10%, respectively). The frequencies 
of the fimbrial serotypes in the five countries were significantly different (P < 0.0001). The 
frequencies of the serotypes in vaccinated and unvaccinated individuals (not shown) were not 
significantly different (P = 0.65).  
DISCUSSION 
  
As part of a European research program for improved B. pertussis strain characterization and 
surveillance, we compared the population structures of B. pertussis in five European 
countries: Finland, Sweden, Germany, The Netherlands, and France. VNTR typing of the 102 
clinical isolates revealed the presence of 16 different VNTR types. The frequencies of the 
VNTR types in the five countries were significantly different (P = 0.0066). This may reflect 
geographic isolation of the populations or local factors such as differences in populations and 
vaccines used. However, the frequencies of VNTR types did not differ significantly in 
vaccinated and unvaccinated hosts or in populations vaccinated with ACVs and WCVs (P = 
0.95). It should be noted that the vaccination status of the Finnish and Dutch patients was 
deduced from their age, which is reasonable in view of the high vaccination coverage. 
However, this may overestimate the fraction of vaccinated individuals, as unvaccinated hosts 
will be more susceptible to infection than vaccinated hosts.  
The majority of isolates in Sweden, Germany, The Netherlands, and France were represented 
by the VNTR types VT27 and VT29 (75 to 90%). Among the Finnish isolates, the VNTR types 
VT27 and VT28 dominated (frequencies of 30% and 25%, respectively). With respect to VNTR 
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types, the Finnish B. pertussis population was quite distinct compared to the other four 
countries. The highest and lowest GD based on VNTR typing were found in Finland (GD, 
0.80) and France (GD, 0.51), respectively. A low genetic diversity was also observed in The 
Netherlands (GD, 0.52). The differences in genotypic diversity may have several causes. The 
high genotypic diversity in Finland may be due to a low human population density resulting in 
isolated B. pertussis populations. The low genotypic diversity observed in the Dutch B. 
pertussis population may be due the expansion of a distinct strain in recent years (38).  
The frequencies of a number of alleles for virulence factors were also studied. Previous 
studies have revealed very little polymorphism in B. pertussis surface proteins. (5, 18, 21, 22, 
28, 38). We focused on genes for proteins incorporated in the ACVs and which were shown to 
be polymorphic in previous studies: ptxC, ptxA, and prn. Further, although tcfA is not part of 
ACVs, it was also included as it was found to be highly polymorphic in a previous study (38). 
Finally, isolates were serotyped to determine the type of fimbriae produced. Fimbriae are part 
of a number of ACVs. However, the ACVs used in some of the five countries did not contain 
fimbriae at the time the isolates were collected (Table 1). The largest difference between 
countries was observed with respect to the ptxC allele (P = 0.0001). We found that the ptxC1 
allele occurred more frequently in Finland (80%) and Sweden (68%) than in the more 
southern countries investigated (24% to 30%). In these latter countries, the ptxC2 allele 
predominated. Interestingly, the two alleles observed differ in a silent mutation. In The 
Netherlands, a recent expansion of the ptxC2 allele was observed, suggesting this allele is 
linked to an as yet unidentified locus which confers a selective advantage (38) The 
frequencies of the ptxC alleles did not differ significantly in vaccinated and unvaccinated hosts 
or in countries using ACVs and WCVs (P = 0.53 and 0.69, respectively).  
Within the population tested, we found no polymorphism in the ptxA gene: all strains were of 
the nonvaccine type ptxA1. These results are consistent with previous studies which revealed 
that, in Finland, The Netherlands, and France, vaccine-type alleles were replaced by 
nonvaccine types (21, 22, 40).  
The pertactin gene (prn) is one of the most polymorphic B. pertussis genes investigated. The 
vaccine-type allele (prn1) was found in very low frequency (0 to 6%) in all countries, whereas 
the nonvaccine-type alleles (prn2 and prn3) were found in frequencies of 75 to 95% and 0 to 
20%, respectively. Previous work showed that, in Finland and The Netherlands, the frequency 
of prn1 decreased from approximately 100% to the present level after introduction of 
nationwide vaccination (21, 22). Stratifying the B. pertussis strains according to country of 
origin, vaccination status of host, or type of vaccine used (WCV or ACV) did not reveal 
significant differences in prn allele frequencies. However, the three isolates expressing the 
vaccine-type allele were found in unvaccinated hosts only (ages 2, 4, and 51 months, 
respectively).  
Of the two tcfA alleles detected, tcfA2 predominated in all five countries (frequencies, 80% to 
100%). TcfA is not part of ACVs; however, it is found in WCVs. The Dutch WCV isolates 
contain the tcfA2 allele, and it is perhaps somewhat unexpected that this allele is predominant 
in The Netherlands. We presume that this may be due to its linkage with the prn2 allele (38). 
Consistent with a previous study using Dutch strains, we found that 97% of the tcfA2 strains 
carried prn2, and 91% of the tcfA3 strains carried prn3. If the prn2 allele confers a larger 
degree of fitness on strains than the prn3 allele, tcfA2 may hitchhike to predominance. 
Stratifying the B. pertussis isolates according to country of origin, vaccination status of host, or 
type of vaccine used (WCV or ACV) did not reveal significant differences in tcfA allele 
frequencies.  
Serotype 2 isolates predominated in Finland and Sweden (frequencies of 90% and 56%, 
respectively), whereas serotype 3 isolates were found to predominate in Germany, The 
Netherlands, and France (frequencies of 94%, 85%, and 90%, respectively). The serotype 
frequencies were significantly different when isolates were stratified according to country of 
origin (P < 0.0001). Interestingly, serotype 3 isolates normally predominate in populations 
vaccinated with WCVs (3, 4, 9, 30, 31). In Sweden, serotype 2 fimbriae predominated in 1979 
to 1996, the vaccine-free period; in 2003, serotype 3 fimbriae replaced serotype 2 fimbriae as 
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the most prevalent serotype, reaching a frequency of more than 90%. The 25 Swedish 
isolates analyzed in this study are part of a total of 589 isolates that were collected in the 
period 1999 to 2000 and which comprised 35% serotype 2 fimbria isolates. It is unclear if there 
is a causal relationship between the introduction of ACVs and the change in serotypes in 
Sweden. It has been suggested that some ACVs are contaminated with fimbriae (2). 
Stratifying the B. pertussis isolates according to vaccination status of host or type of vaccine 
used (WCV or ACV) did not reveal significant differences in serotype frequencies.  
The present study reveals a relationship between geographic location and VNTR types, the 
frequency of the ptxC alleles, and serotypes. Further studies are required to elucidate the 
underlying causes. We have not observed a relationship between the strain characteristics we 
studied and vaccination programs. This may be due to the fact that some vaccines have been 
introduced recently or to the limited number of strains analyzed. The relative contribution of 
geography and vaccination in the genesis of distinct B. pertussis populations in Europe 
requires further study. This work may serve as a baseline for future studies and may ultimately 
lead to a more efficient vaccination against pertussis. PCR is replacing culture in the 
diagnosis of pertussis, and this has hampered the collection of strains for epidemiological 
studies. We recommend the implementation of a system to actively collect Bordetella strains 
in Europe. Strains can be characterized according to standard procedures (20, 38). Further, 
data should be collected on the date and place of isolation, patient age and vaccination status, 
and the vaccine used. Although antibiotic resistance in B. pertussis is rare, future studies may 
include this aspect also (41).  
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